PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth of 41.00% while Biotechnology median is zero. Walter Schloss might see a slight advantage that could be built upon.
27.93%
Positive EBIT growth while Biotechnology median is negative. Peter Lynch might see a strong competitive advantage in operations.
27.93%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
29.77%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
30.61%
EPS growth of 30.61% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
30.61%
Diluted EPS growth of 30.61% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
2.13%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.13%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
32.67%
OCF growth of 32.67% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
32.86%
FCF growth of 32.86% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
OCF/share CAGR of 83.05% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
75.83%
OCF/share CAGR of 75.83% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
20.41%
3Y OCF/share growth > 1.5x Biotechnology median of 1.84%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
95.17%
Net income/share CAGR of 95.17% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
79.59%
Net income/share CAGR of 79.59% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
2.82%
3Y net income/share CAGR > 1.5x Biotechnology median of 1.84%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
170.99%
Equity/share CAGR of 170.99% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-42.91%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-60.55%
Negative 3Y equity/share growth while Biotechnology median is -21.97%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reductions while Biotechnology median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-18.27%
Negative BV/share change while Biotechnology median is -6.86%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-4.43%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-31.86%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-15.50%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.